ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm
Executive Summary
The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS’ targeted oncology acquisition; a snapshot of the multiple sclerosis market; and a look at Aduhelm one year later.
AstraZeneca/Daiichi's Enhertu Expansion Strategy Progresses With New Approval
Enhertu secured US FDA approval as a second-line treatment in HER2-positive breast cancer, where it is poised to become the new standard of care.
AstraZeneca and Daiichi Sankyo’s Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data
Transformative product is the first to demonstrate benefit in HER2-low metastatic breast cancer, broadening its market potential to nearly half of all breast cancers.